"Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)." by Jorge E. Cortes

Selected Works of John M. Pagel, MD, PhD

Follow Contact

Article

Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Journal of Clinical Oncology (2015)

Jorge E. Cortes, University of Texas Health Science Center at Houston
Stefan Faderl, University of Texas MD Anderson Cancer Center
John Pagel, Cancer Institute
Chul Won Jung, Samsung Medical Center
Sung-Soo Yoon, Seoul National University Hospital
Youngil Koh, Seoul National University
Animesh Dev Pardanani, Mayo Clinic
Robert S Hauptschein
Kyoung-June Lee
Je-Hwan Lee, Fred Hutchinson Cancer Research Center

Link

Disciplines

Medicine and Health Sciences and
Pathology

Publication Date

May 20, 2015

Citation Information

Jorge E. Cortes, Stefan Faderl, John Pagel, Chul Won Jung, et al.. "Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)." Journal of Clinical Oncology Vol. 33 (2015) p. 7044
Available at: http://works.bepress.com/john-pagel/59/